WO2012037299A3 - Fatty acid synthase inhibitors - Google Patents
Fatty acid synthase inhibitors Download PDFInfo
- Publication number
- WO2012037299A3 WO2012037299A3 PCT/US2011/051672 US2011051672W WO2012037299A3 WO 2012037299 A3 WO2012037299 A3 WO 2012037299A3 US 2011051672 W US2011051672 W US 2011051672W WO 2012037299 A3 WO2012037299 A3 WO 2012037299A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- acid synthase
- synthase inhibitors
- relates
- triazolethiones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
This invention relates to the use of triazolone and triazolethione derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones and triazolethiones in the treatment of cancer.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013529311A JP2014508097A (en) | 2010-09-17 | 2011-09-15 | Fatty acid synthase inhibitor |
EP11825905.0A EP2616071A2 (en) | 2010-09-17 | 2011-09-15 | Fatty acid synthase inhibitors |
US13/824,000 US20130172384A1 (en) | 2010-09-17 | 2011-09-15 | Fatty acid synthase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38377410P | 2010-09-17 | 2010-09-17 | |
US61/383,774 | 2010-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012037299A2 WO2012037299A2 (en) | 2012-03-22 |
WO2012037299A3 true WO2012037299A3 (en) | 2014-03-27 |
Family
ID=45832231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/051672 WO2012037299A2 (en) | 2010-09-17 | 2011-09-15 | Fatty acid synthase inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US20130172384A1 (en) |
EP (1) | EP2616071A2 (en) |
JP (1) | JP2014508097A (en) |
WO (1) | WO2012037299A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505728B2 (en) | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
EP2892892B1 (en) * | 2012-09-07 | 2017-05-31 | Janssen Pharmaceutica NV | Imidazolin-5-one derivatives useful as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
MX2015007433A (en) * | 2012-12-20 | 2015-12-07 | Inception 2 Inc | Triazolone compounds and uses thereof. |
EP2943484B1 (en) * | 2013-01-10 | 2017-10-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Fatty acid synthase inhibitors |
PE20160122A1 (en) | 2013-03-13 | 2016-02-12 | Forma Therapeutics Inc | NOBLE COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN |
WO2015035059A1 (en) | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CA2934257C (en) * | 2013-12-17 | 2022-06-07 | Janssen Pharmaceutica Nv | Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer |
TW201722958A (en) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | Chemical compounds |
TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
CN113382633A (en) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone |
CN111777593A (en) * | 2019-04-03 | 2020-10-16 | 南京天印健华医药科技有限公司 | Novel compounds as inhibitors of rearrangement kinase during transfection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116491A1 (en) * | 2002-10-07 | 2004-06-17 | King Bryan W. | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme |
US20100022540A1 (en) * | 2006-05-18 | 2010-01-28 | Hans-Michael Eggenweiler | Triazole derivatives ii |
-
2011
- 2011-09-15 US US13/824,000 patent/US20130172384A1/en not_active Abandoned
- 2011-09-15 WO PCT/US2011/051672 patent/WO2012037299A2/en active Application Filing
- 2011-09-15 JP JP2013529311A patent/JP2014508097A/en not_active Withdrawn
- 2011-09-15 EP EP11825905.0A patent/EP2616071A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040116491A1 (en) * | 2002-10-07 | 2004-06-17 | King Bryan W. | Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme |
US20100022540A1 (en) * | 2006-05-18 | 2010-01-28 | Hans-Michael Eggenweiler | Triazole derivatives ii |
Also Published As
Publication number | Publication date |
---|---|
EP2616071A2 (en) | 2013-07-24 |
JP2014508097A (en) | 2014-04-03 |
WO2012037299A2 (en) | 2012-03-22 |
US20130172384A1 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012037299A3 (en) | Fatty acid synthase inhibitors | |
EA201290822A1 (en) | TRIAZOLONES AS FATTY ACIDS SYNTHASE INHIBITORS | |
WO2012096928A3 (en) | Pyrimidinone derivatives as fatty acid synthase inhibitors | |
IL264441A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
EP2615918A4 (en) | Fatty acid synthase inhibitors | |
EP2488025A4 (en) | Sepiapterin reductase inhibitors for the treatment of pain | |
MX369832B (en) | Liquid formulation. | |
WO2013023084A3 (en) | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
WO2012058211A3 (en) | Quinazoline derivatives, compositions, and uses related thereto | |
WO2014004572A3 (en) | Modulation of ube3a-ats expression | |
WO2012065019A3 (en) | Combination comprising pyridopyrimidinone inhibitors of pi3k alpha | |
WO2012054862A9 (en) | Agents, compositions, and methods for treating pruritis and related skin conditions | |
WO2011142970A3 (en) | Her2 nucleic acid aptamers | |
WO2012065139A8 (en) | Entpd5 inhibitors | |
WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
EP2603216A4 (en) | Heteroaryls and uses thereof | |
AU2010306870A8 (en) | Reducing the risk of pathological effects of traumatic brain injury | |
WO2012073047A3 (en) | Compositions and methods | |
WO2011126842A3 (en) | Targeting micrornas for the treatment of cardiac disorders | |
WO2013169631A3 (en) | Wnt protein signalling inhibitors | |
WO2012104240A3 (en) | Cosmetic use | |
WO2013037943A8 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
EP2576536A4 (en) | Haematopoietic-prostaglandin d2 synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11825905 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2013529311 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13824000 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011825905 Country of ref document: EP |